Combining a TKI with bicalutamide in men with CRPC

We have reported on a number of attempts to use tyrosine kinase inhibitors (TKIs) — alone or in combination with chemotherapy — in the treatment of men with castration-resistant prostate cancer (CRPC). Limited activity or efficacy has been reported to date. … READ MORE …

Adding a TKI to docetaxel + prednisone for men with mCRPC

One of the great unanswered questions (so far) is whether adding a tyrosine kinase inhibitor (a TKI) to docetaxel + prednisone can improve outcomes for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Tykerb not effective in treatment of prostate cancer

Like many other drugs before it, lapatinib (Tykerb/GlaxoSmithKline) appears to have very limited clinical activity in prostate cancer according to a recently published report. … READ MORE …